What is the recommended dose of doxofylline for adult patients with conditions such as chronic obstructive pulmonary disease, asthma, or bronchospasm?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Doxofylline Dosing in Adults

The recommended dose of doxofylline for adults with COPD, asthma, or bronchospasm is 400 mg three times daily (1200 mg total daily dose). 1, 2, 3

Standard Dosing Regimen

For chronic obstructive pulmonary disease and asthma, administer doxofylline 400 mg orally three times daily. This dosing has been validated in multiple clinical trials and demonstrates optimal bronchodilator efficacy with acceptable tolerability 1, 2, 3.

Key Dosing Details:

  • Standard adult dose: 400 mg three times daily (TID)
  • Total daily dose: 1200 mg
  • Route: Oral administration
  • Duration: Can be used for chronic maintenance therapy (studied up to 12 weeks in clinical trials) 2

Evidence Supporting This Dose

The 400 mg TID regimen has been specifically studied and shown to:

  • Significantly improve spirometric parameters (FEV1, FVC, FEF25-75%) compared to placebo 2
  • Reduce asthma attack rates and rescue bronchodilator use 2
  • Achieve therapeutic serum levels of 12-15 mcg/mL, which correlates with bronchodilator efficacy 3
  • Demonstrate superior tolerability compared to theophylline at equivalent bronchodilator doses 1, 2

Lower Dose Consideration

A 200 mg TID dose (600 mg total daily) has been studied but showed minimal differences from placebo in clinical trials 2. This lower dose is not recommended for achieving meaningful bronchodilation in adults with moderate to severe airway obstruction.

Clinical Context and Positioning

Doxofylline should be considered as add-on therapy in patients with COPD or asthma who remain symptomatic despite standard bronchodilator therapy. While established COPD guidelines 4, 5, 6 recommend inhaled bronchodilators (beta-agonists and anticholinergics) as first-line therapy, methylxanthines like doxofylline can be tried in patients with severe disease who need additional bronchodilation, particularly when they demonstrate responsiveness to beta-agonists 4.

When to Use Doxofylline:

  • Patients with moderate to severe COPD (FEV1 <60% predicted) inadequately controlled on inhaled bronchodilators 1, 3
  • Patients with chronic reversible asthma requiring additional controller therapy 2
  • Particularly effective in patients who show acute response to inhaled beta-2 agonists (>20% FEV1 improvement) 3

Safety and Monitoring

Doxofylline demonstrates significantly better tolerability than theophylline, with fewer adverse events and lower dropout rates 1, 2. In comparative trials:

  • Adverse event rate: 8 events with doxofylline vs. 25 with theophylline 1
  • Treatment discontinuation: 5 patients on doxofylline vs. 10 on theophylline 1
  • Number needed to treat to spare one dropout: 5 patients 2

Important Safety Points:

  • No routine serum level monitoring required (unlike theophylline) 1, 2
  • Common side effects include dyspepsia, nausea, and anxiety, but occur less frequently than with theophylline 3
  • Therapeutic serum range appears to be 12-15 mcg/mL based on pharmacokinetic studies 3
  • Elimination half-life is approximately 7 hours after oral administration 7

Critical Caveats

Do not confuse doxofylline with doxepin - the FDA drug label information provided 8 refers to doxepin (a tricyclic antidepressant used for insomnia at 3-6 mg doses), which is an entirely different medication with no role in respiratory disease.

Doxofylline is not available in all markets - it is primarily used in Europe, Asia, and some other regions but is not FDA-approved in the United States. The evidence base, while positive, consists primarily of smaller trials rather than large-scale international studies 1, 2, 3.

References

Research

Oral doxophylline in patients with chronic obstructive pulmonary disease.

International journal of clinical pharmacology and therapeutics, 1997

Related Questions

Can doxofylline be used continuously for one year in patients with chronic airway disease such as COPD or asthma?
Can a patient with chronic obstructive pulmonary disease (COPD) take doxofylline capsules daily?
Can I continue doxofylline 400 mg daily for an asthmatic patient for an additional 2–3 weeks?
What are the indications, recommended adult dosing, contraindications, precautions, side effects, and monitoring recommendations for doxofylline?
What are the recommended dosing regimens of doxofylline for adults and pediatric patients?
Is it appropriate to prescribe EzPAP (EzPAP device) for all residents in a skilled‑nursing or long‑term‑care facility as a blanket preventive measure regardless of diagnosis, and can it be billed under Medicare Part A?
Can my bladder cancer (non‑invasive or invasive) affect my appetite while awaiting pathology results?
What is the elimination half‑life of venlafaxine 25 mg and how long does it take for the drug and its active metabolite to be cleared from the body?
In a female patient in her late 80s with advanced lung cancer, brain metastases, opioid‑related nausea, bradycardia, hypertension, fever, and left‑eye movement limitation, what is the most appropriate first‑line anti‑emetic?
In patients receiving chronic amiodarone therapy, should routine chest X‑ray (CXR) and pulmonary function testing (PFT) be performed annually to monitor for pulmonary toxicity?
What are the differences in ventilator settings for non‑invasive ventilation (NIV) in acute exacerbation of chronic obstructive pulmonary disease (COPD) versus acute cardiogenic pulmonary edema?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.